218 related articles for article (PubMed ID: 19383215)
21. Plasma fluoxetine concentrations and clinical improvement in an adolescent sample diagnosed with major depressive disorder, obsessive-compulsive disorder, or generalized anxiety disorder.
Blázquez A; Mas S; Plana MT; Gassó P; Méndez I; Torra M; Arnaiz JA; Lafuente A; Lázaro L
J Clin Psychopharmacol; 2014 Jun; 34(3):318-26. PubMed ID: 24743718
[TBL] [Abstract][Full Text] [Related]
22. Adjunctive sleep medications and depression outcome in the treatment of serotonin-selective reuptake inhibitor resistant depression in adolescents study.
Shamseddeen W; Clarke G; Keller MB; Wagner KD; Birmaher B; Emslie GJ; Ryan N; Asarnow JR; Porta G; Brent DA
J Child Adolesc Psychopharmacol; 2012 Feb; 22(1):29-36. PubMed ID: 22251024
[TBL] [Abstract][Full Text] [Related]
23. Differential outcomes from metabolic ratios in the identification of CYP2D6 phenotypes--focus on venlafaxine and O-desmethylvenlafaxine.
Kandasamy M; Srinivas P; Subramaniam K; Ravi S; John J; Shekar R; Srinivas N; Thangam S
Eur J Clin Pharmacol; 2010 Sep; 66(9):879-87. PubMed ID: 20446083
[TBL] [Abstract][Full Text] [Related]
24. Distribution of venlafaxine, O-desmethylvenlafaxine, and O-desmethylvenlafaxine to venlafaxine ratio in postmortem human brain tissue.
Murrell MD; Cruz DA; Javors MA; Thompson PM
J Forensic Sci; 2014 May; 59(3):683-9. PubMed ID: 24502274
[TBL] [Abstract][Full Text] [Related]
25. Omega-3 fatty acid deficient male rats exhibit abnormal behavioral activation in the forced swim test following chronic fluoxetine treatment: association with altered 5-HT1A and alpha2A adrenergic receptor expression.
Able JA; Liu Y; Jandacek R; Rider T; Tso P; McNamara RK
J Psychiatr Res; 2014 Mar; 50():42-50. PubMed ID: 24360505
[TBL] [Abstract][Full Text] [Related]
26. Effects of different doses of venlafaxine on serotonin and norepinephrine reuptake in healthy volunteers.
Blier P; Saint-André E; Hébert C; de Montigny C; Lavoie N; Debonnel G
Int J Neuropsychopharmacol; 2007 Feb; 10(1):41-50. PubMed ID: 16690005
[TBL] [Abstract][Full Text] [Related]
27. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression.
Corya SA; Williamson D; Sanger TM; Briggs SD; Case M; Tollefson G
Depress Anxiety; 2006; 23(6):364-72. PubMed ID: 16710853
[TBL] [Abstract][Full Text] [Related]
28. Comparative bioavailability of fluoxetine after transdermal and oral administration to healthy cats.
Ciribassi J; Luescher A; Pasloske KS; Robertson-Plouch C; Zimmerman A; Kaloostian-Whittymore L
Am J Vet Res; 2003 Aug; 64(8):994-8. PubMed ID: 12926591
[TBL] [Abstract][Full Text] [Related]
29. Increasing serotonin bioavailability in preweaned dairy calves impacts hematology, growth, and behavior.
Marrero MG; Dado-Senn B; Field SL; da Silva DR; Skibiel AL; Laporta J
Domest Anim Endocrinol; 2019 Oct; 69():42-50. PubMed ID: 31280025
[TBL] [Abstract][Full Text] [Related]
30. Risk factors for stereotypic behavior and self-biting in rhesus macaques (Macaca mulatta): animal's history, current environment, and personality.
Gottlieb DH; Capitanio JP; McCowan B
Am J Primatol; 2013 Oct; 75(10):995-1008. PubMed ID: 23640705
[TBL] [Abstract][Full Text] [Related]
31. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study.
Meyer JH; Wilson AA; Sagrati S; Hussey D; Carella A; Potter WZ; Ginovart N; Spencer EP; Cheok A; Houle S
Am J Psychiatry; 2004 May; 161(5):826-35. PubMed ID: 15121647
[TBL] [Abstract][Full Text] [Related]
32. Concomitant use of tramadol and venlafaxine - evaluation of antidepressant-like activity and other behavioral effects in rats.
Szkutnik-Fiedler D; Kus K; Balcerkiewicz M; Grześkowiak E; Nowakowska E; Burda K; Ratajczak P; Sadowski C
Pharmacol Rep; 2012; 64(6):1350-8. PubMed ID: 23406745
[TBL] [Abstract][Full Text] [Related]
33. Lack of a pharmacokinetic drug-drug interaction with venlafaxine extended-release/indinavir and desvenlafaxine extended-release/indinavir.
Jann MW; Spratlin V; Momary K; Zhang H; Turner D; Penzak SR; Wright A; VanDenBerg C
Eur J Clin Pharmacol; 2012 May; 68(5):715-21. PubMed ID: 22173281
[TBL] [Abstract][Full Text] [Related]
34. Influence of sex and menopausal status on response, remission, and recurrence in patients with recurrent major depressive disorder treated with venlafaxine extended release or fluoxetine: analysis of data from the PREVENT study.
Kornstein SG; Pedersen RD; Holland PJ; Nemeroff CB; Rothschild AJ; Thase ME; Trivedi MH; Ninan PT; Keller MB
J Clin Psychiatry; 2014 Jan; 75(1):62-8. PubMed ID: 24345717
[TBL] [Abstract][Full Text] [Related]
35. A randomized double-blind, placebo-controlled trial of venlafaxine-extended release for co-occurring cannabis dependence and depressive disorders.
Levin FR; Mariani J; Brooks DJ; Pavlicova M; Nunes EV; Agosti V; Bisaga A; Sullivan MA; Carpenter KM
Addiction; 2013 Jun; 108(6):1084-94. PubMed ID: 23297841
[TBL] [Abstract][Full Text] [Related]
36. Effects of fluoxetine and norfluoxetine on 5-hydroxytryptamine metabolism in blood platelets and brain after administration to rats.
Bourdeaux R; Desor D; Lehr PR; Younos C; Capolaghi B
J Pharm Pharmacol; 1998 Dec; 50(12):1387-92. PubMed ID: 10052854
[TBL] [Abstract][Full Text] [Related]
37. Was the exacerbation of PTSD symptoms after high doses of venlafaxine due to the noradrenergic mechanism? A case report.
da Rocha FF; Correa H
Braz J Psychiatry; 2007 Mar; 29(1):94. PubMed ID: 17435946
[No Abstract] [Full Text] [Related]
38. Pharmacokinetic and pharmacodynamic interactions between fluoxetine and moclobemide in the investigation of development of the "serotonin syndrome".
Dingemanse J; Wallnöfer A; Gieschke R; Guentert T; Amrein R
Clin Pharmacol Ther; 1998 Apr; 63(4):403-13. PubMed ID: 9585794
[TBL] [Abstract][Full Text] [Related]
39. Evidence of the dual mechanisms of action of venlafaxine.
Harvey AT; Rudolph RL; Preskorn SH
Arch Gen Psychiatry; 2000 May; 57(5):503-9. PubMed ID: 10807491
[TBL] [Abstract][Full Text] [Related]
40. Venlafaxine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder.
Findling RL; Greenhill LL; McNamara NK; Demeter CA; Kotler LA; O'Riordan MA; Myers C; Reed MD
J Child Adolesc Psychopharmacol; 2007 Aug; 17(4):433-45. PubMed ID: 17822339
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
